GSK expands RSV vaccine access in the U.S., highlighting structural gaps in global vaccine equity
Original framing: “GSK gets US FDA approval for expanded use of RSV vaccine - Reuters” — Reuters (via Google News)
The original framing omits the role of pharmaceutical patents, the lack of technology transfer to low-income countries, and the absence of indigenous and community-led health solutions in vaccine development. It also fails to address the historical context of vaccine inequity, such as the COVAX failures during the pandemic.
Medium structural omission detected in mainstream coverage.
This narrative is produced by Reuters, a major global news agency, and is likely intended for investors, policymakers, and health professionals in the Global North. The framing serves pharmaceutical industry interests by emphasizing regulatory progress while obscuring the structural barriers that prevent equitable vaccine access in the Global South.
The pattern of vaccine inequity is not new; it echoes the COVAX failures during the pandemic, where wealthy nations secured most doses while poorer countries waited. Historical precedents show that without binding international agreements, vaccine access remains stratified along economic lines.
The FDA approval of GSK's expanded RSV vaccine in the U.S. underscores the systemic inequities in global vaccine access.